Related Experiment Video

Updated: Apr 26, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.3K

Pharmaceutical approval update

Marvin M Goldenberg

    P & T : a Peer-Reviewed Journal for Formulary Management
    |August 2, 2014
    PubMed

    Insights

    New therapies Albiglutide for type-2 diabetes, Ramucirumab for gastric cancer, and Ceritinib for non-small-cell lung cancer show promise. These treatments offer new options for patients with these serious conditions.

    Area of Science:

    • Oncology
    • Endocrinology

    Background:

    • Type-2 diabetes, gastric cancer, and non-small-cell lung cancer represent significant global health challenges.
    • Existing treatments have limitations, necessitating the development of novel therapeutic agents.

    Purpose of the Study:

    • To review the therapeutic applications of Albiglutide, Ramucirumab, and Ceritinib.
    • To highlight their efficacy in specific patient populations and cancer types.

    Main Methods:

    • Review of clinical trial data and regulatory submissions for Albiglutide (Tanzeum), Ramucirumab (Cyramza), and Ceritinib (Zykadia).
    • Analysis of efficacy and safety profiles in target patient groups.

    Main Results:

    • Albiglutide demonstrates efficacy in managing type-2 diabetes.
    • Ramucirumab shows activity in advanced or metastatic gastric and gastro-esophageal junction adenocarcinoma.
    • Ceritinib is effective for metastatic non-small-cell lung cancer.

    Conclusions:

    • Albiglutide, Ramucirumab, and Ceritinib offer valuable new treatment options.
    • These agents expand therapeutic strategies for type-2 diabetes and specific advanced cancers.

    More Related Videos

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    9.6K
    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    740

    Related Concept Videos

    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    340
    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

    PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
    97
    Drug Regulation01:25

    Drug Regulation

    Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
    3.0K
    Drug Administration and Therapy Phases: Overview01:26

    Drug Administration and Therapy Phases: Overview

    Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
    The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
    The pharmacokinetic phase...
    1.9K
    Clinical Trials: Overview01:11

    Clinical Trials: Overview

    Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
    4.7K
    Drug Products: Biologics, Biosimilars and Interchangeables01:28

    Drug Products: Biologics, Biosimilars and Interchangeables

    Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
    369